BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35507054/
The choice of BTK inhibitor is guided by the setting (frontline vs relapsed) in conjunction with patient disease characteristics and comorbidities. In this review, we will elucidate our approach to...
Expert opinion: The choice of BTK inhibitor is guided by the setting (frontline vs relapsed) in conjunction with patient disease characteristics and comorbidities. In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy.
The role of BTK inhibitors on the tumor microenvironment in CLL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35465824/
The CLL disease course is heterogeneous with many patients never requiring treatment and some having very aggressive rapid onset disease.Innate and adaptive immune compensatory mechanisms driven by malignant cells often...
Relevance: In this review article we look at role of BTK in the pathogenesis of CLL, the use of BTKi and their effect on humoral immunity.
New Mechanisms of Genomic Escape From Noncovalent BTK Inhibitors
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029896/
In physiological conditions, B-cell receptor (BCR) signaling promotes B-cell development and maintenance by activating proliferative and survival pathways. In pathological conditions, these pathways are co-opted by malignant B-cells to promote...
Relevance: Despite the small number of patients analyzed in this study, data provided by Wang et al2 are important as they suggest novel therapeutic approaches to overcome BTK inhibitors resistance.
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients
Gage S. Black, Xiaomeng Huang, Yi Qiao, Szabolcs Tarapcsak, Kerry A. Rogers, Shrilekha Misra, John C. Byrd, Gabor T. Marth, Deborah M. Stephens, Jennifer A. Woyach; Subclonal evolution of CLL...
Conclusion/Relevance: Understanding the clonal evolution within patients treated with either of these BTKis can help determine how well a patient maintains response to treatment and if BTKi treatment should be modified or another agent should be added to deepen response.
![[ 18 F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase - PubMed](https://static-content-prd.skipta.com/public/skipta/skipta-post/2023-12/fileQtlkx5 "[ 18 F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase - PubMed")
[ 18 F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35482146/
doi: 10.1007/s11307-022-01733-1. Online ahead of print. 1 AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL, 60064, USA. 2 AbbVie, 1000 Gateway Blvd, South San Francisco, CA, 94080, USA. 3...
Conclusion: [18F]BTK-1 is a promising PET tracer for imaging of BTK, which could provide valuable information for patient selection, drug dose determination, and improving our understanding of BTK biology in humans.